Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $12.00 at KeyCorp

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) had its price objective dropped by analysts at KeyCorp from $16.00 to $12.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s target price indicates a potential upside of 65.98% from the company’s previous close.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, June 25th.

Read Our Latest Stock Analysis on RXRX

Recursion Pharmaceuticals Stock Down 2.8 %

NASDAQ:RXRX opened at $7.23 on Thursday. Recursion Pharmaceuticals has a 12-month low of $4.97 and a 12-month high of $16.75. The firm has a market capitalization of $1.72 billion, a PE ratio of -4.52 and a beta of 0.83. The firm has a 50-day moving average price of $8.74 and a 200 day moving average price of $9.81.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The firm had revenue of $13.80 million during the quarter, compared to analyst estimates of $11.10 million. During the same quarter in the prior year, the business posted ($0.34) earnings per share. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. On average, research analysts expect that Recursion Pharmaceuticals will post -1.56 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other news, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total transaction of $386,500.00. Following the sale, the chief executive officer now directly owns 863,524 shares of the company’s stock, valued at $6,675,040.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Tina Marriott sold 3,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $8.78, for a total transaction of $26,340.00. Following the sale, the chief operating officer now directly owns 535,457 shares of the company’s stock, valued at $4,701,312.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total transaction of $386,500.00. Following the sale, the chief executive officer now directly owns 863,524 shares in the company, valued at $6,675,040.52. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 207,359 shares of company stock valued at $1,704,435. Corporate insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $26,000. National Bank of Canada FI raised its holdings in shares of Recursion Pharmaceuticals by 90.9% during the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares during the period. First Horizon Advisors Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $47,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the period. Finally, Oxford Wealth Group LLC acquired a new stake in shares of Recursion Pharmaceuticals during the first quarter worth $106,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Recommended Stories

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.